methylone and Heart-Defects--Congenital

methylone has been researched along with Heart-Defects--Congenital* in 1 studies

Other Studies

1 other study(ies) available for methylone and Heart-Defects--Congenital

ArticleYear
[A new designer drug: methylone related death].
    Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7

    This report presents a fatal case related to the consumption of methylone, a relatively new cathinone type designer drug. A 16-year-old boy suddenly lost his consciousness in a party. Resuscitation had been continued for about 1.5 hours at the intensive care unit, but it was unsuccessful. His previous history included cardiac malformation detected at infancy and bronchial asthma had been diagnosed one year before his death. Signs of sudden cardiac death were observed during autopsy. Methylone intake was proved in blood and liver extract using gas chromatography/mass spectrometry; its concentration was 272 ng/ml in the blood, and 387 ng/g in the liver. Pathohistology revealed microvascular steatosis in the liver, which raised the possibility of chronic use of toxic substances. In addition, striated heart muscle damage was observed, which could be due to the use of an amphetamine-like substance. The authors presume that steatosis of the heart muscle, congenital heart disease and bronchial asthma could be predisposing factors for sudden cardiac death that occurred in the presence of relatively low levels of methylone. Access to various designer drugs is easy, fast and broad. Consequently, the potential abuse or overdose should be taken into consideration in the emergency practice. The use of "non-illicit" drugs does not require formal intervention by the authorities, but the medical service must alarm the stakeholders.

    Topics: Adolescent; Amphetamine; Asthma; Autopsy; Causality; Death, Sudden, Cardiac; Designer Drugs; Drug Overdose; Fatal Outcome; Fatty Liver; Heart Defects, Congenital; Humans; Hungary; Male; Methamphetamine; Muscle, Smooth; N-Methyl-3,4-methylenedioxyamphetamine

2012